BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced CancerMetastatic Solid TumorAdvanced Solid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT06540066
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 74
- Registration Number
- NCT06487858
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric CancerExtragonadal Yolk Sac TumorsGlypican-3 (GPC3)-Positive Squamous Non-small Cell Lung CancerMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 140
- Registration Number
- NCT06427941
- Locations
- 🇺🇸
Scri Oncology Partners, Nashville, Tennessee, United States
🇺🇸Upmc Hillman Cancer Center, Puyallup, Washington, United States
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06422520
- Locations
- 🇨🇳
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
🇺🇸Florida Cancer Specialist Research Institute Lake Nona, Orlando, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
- Conditions
- Healthy ParticipantsHealthy SubjectsHealthy VolunteersAutoimmune DiseasesHealthy Adult ParticipantsAtopic DermatitisPrurigo Nodularis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 195
- Registration Number
- NCT06342713
- Locations
- 🇦🇺
Innovate Clinical Research, Waitara, New South Wales, Australia
🇦🇺Cmax Clinical Research, Adelaide, South Australia, Australia
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Conditions
- Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 218
- Registration Number
- NCT06257264
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇺🇸Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast CancerBreast CancerMetastatic Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 33
- Registration Number
- NCT06253195
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 227
- Registration Number
- NCT06233942
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorHormone Receptor Positive Malignant Neoplasm of BreastAdvanced Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNon-small Cell Lung CancerHormone Receptor Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 79
- Registration Number
- NCT06120283
- Locations
- 🇧🇷
Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Brazil
🇧🇷Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Brazil
🇺🇸Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06091943
- Locations
- 🇨🇳
Jining No Peoples Hospital East Branch, Jining, Shandong, China
🇨🇳Deyangs People Hospital, Deyang, Sichuan, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China